PMID- 28659990
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2017
DP  - 2017
TI  - Antihepatocarcinoma Effect of Portulaca oleracea L. in Mice by PI3K/Akt/mTOR and 
      Nrf2/HO-1/NF-kappaB Pathway.
PG  - 8231358
LID - 10.1155/2017/8231358 [doi]
LID - 8231358
AB  - The purpose of the present study was to evaluate the pharmacological effects of 
      Portulaca oleracea L. (Purslane) (PL) on N-nitrosodiethylamine- (NDEA-) induced 
      hepatocellular carcinomas (HCC) and explore its potential mechanism. Mice were 
      randomly assigned to four groups: control group, NDEA group, NDEA + Purslane 
      (100 mg/kg) group, and NDEA + Purslane (200 mg/kg) group. The animal of each 
      group was given NDEA (100 ppm) in drinking water. 1 h later, Purslane dissolved 
      in PBS was intragastrically administered for continuous seven days. The results 
      showed that Purslane reduced the activities of alanine aminotransferase (ALT) and 
      aspartate aminotransferase (AST) in liver and serum. Purslane also reduced the 
      contents of interleukin-6 (IL-6), IL-1beta, tumor necrosis factor-alpha (TNF-alpha), and 
      methane dicarboxylic aldehyde (MDA) and restored the activity of superoxygen 
      dehydrogenises (SOD) in serum. Purslane could obviously attenuate the hepatic 
      pathological alteration. Furthermore, treatment with Purslane effectively 
      inhibited the phosphorylations of phosphatidylinositol 3 kinase (PI3K), protein 
      kinase B (Akt), mammalian target of rapamycin (mTOR), nuclear factor-kappa B 
      (NF-kappaB), and inhibitor of NF-kappaBalpha (IkappaBalpha) and upregulated the expressions of 
      NF-E2-related factor 2 (Nrf2) and heme oxygenase- (HO-) 1. In conclusion, our 
      research suggested that Purslane exhibited protective effects on NDEA-induced 
      hepatocellular carcinomas by anti-inflammatory and antioxidative properties via 
      the PI3K/Akt/mTOR and Nrf2/HO-1/NF-kappaB pathway.
FAU - Guoyin, Zheng
AU  - Guoyin Z
AD  - Department of Traditional Chinese Medicine, Changhai Hospital, Second Military 
      Medical University, Shanghai, China.
FAU - Hao, Peng
AU  - Hao P
AD  - Department of Traditional Chinese Medicine, Changhai Hospital, Second Military 
      Medical University, Shanghai, China.
FAU - Min, Li
AU  - Min L
AD  - Department of Traditional Chinese Medicine, Changhai Hospital, Second Military 
      Medical University, Shanghai, China.
FAU - Wei, Gu
AU  - Wei G
AD  - Department of Traditional Chinese Medicine, Changhai Hospital, Second Military 
      Medical University, Shanghai, China.
FAU - Zhe, Chen
AU  - Zhe C
AD  - Department of Traditional Chinese Medicine, Changhai Hospital, Second Military 
      Medical University, Shanghai, China.
FAU - Changquan, Ling
AU  - Changquan L
AUID- ORCID: 0000-0002-3773-8127
AD  - Department of Traditional Chinese Medicine, Changhai Hospital, Second Military 
      Medical University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20170604
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC5474246
EDAT- 2017/07/01 06:00
MHDA- 2017/07/01 06:01
PMCR- 2017/06/04
CRDT- 2017/06/30 06:00
PHST- 2016/09/13 00:00 [received]
PHST- 2016/12/06 00:00 [accepted]
PHST- 2017/06/30 06:00 [entrez]
PHST- 2017/07/01 06:00 [pubmed]
PHST- 2017/07/01 06:01 [medline]
PHST- 2017/06/04 00:00 [pmc-release]
AID - 10.1155/2017/8231358 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2017;2017:8231358. doi: 10.1155/2017/8231358. 
      Epub 2017 Jun 4.